OPKO Health, Inc. (OPK)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$1.64+1.86%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · OPK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -82.2% |
| Our one-year growth estimate | diamond | 0.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 82.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 32 industry peers · Company calendar date is not available
OPK — capital allocation — Creation of a Direct Financial Obligation or an Obligation under an Off-Balan…
Dated 2026-08-14
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The description in
Why it matters: Early results could support OPKO's method for treating metabolic disorders. This may affect future trials.
Supportive ifInitial safety and drug data from OPK-88006 shows good results.
Worry ifInitial data from the trial shows safety concerns or lack of efficacy.
Why it matters: Earnings reports can explain management's view and how they meet their goals.
Watch forEarnings report shows better revenue guidance.
Also watch forEarnings report shows lower revenue guidance.
Why it matters: Finishing enrollment would show progress in OPKO's cancer treatments. It may open market chances.
Supportive ifMDX2003 Phase 1 trial enrollment is completed ahead of schedule.
Worry ifEnrollment is delayed or falls short of targets.
Why it matters: Moving these trials forward could prove OPKO's new therapies and help investor trust.
Supportive ifModeX enters Phase 1 studies for CAR T therapies by early 2027.
Worry ifPhase 1 studies are delayed beyond early 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$136 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $355 loss on $10,000 · 3.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,038 loss on $10,000 · 30.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Filing an IND would show progress in OPKO's work with Entera Bio and market entry.
Supportive ifAn announcement says the IND application has been sent to the FDA.
Worry ifNews that the IND application will be delayed or not filed as planned.
Why it matters: If healthcare sector revenue growth speeds up, it may help OPKO's performance. This could signal a better environment for OPKO.
Supportive ifHealthcare sector revenue growth exceeds 10% year over year.
Worry ifHealthcare sector revenue growth remains below 10% year over year.
Why it matters: Finishing enrollment would show progress in OPKO's metabolic disease work. It may lead to more money.
Supportive ifEnrollment for OPK-88006 in presumed MASH participants is completed by the end of Q3 2026.
Worry ifEnrollment is late past Q3 2026. This suggests possible problems in development.
Why it matters: Good results could help OPKO's COVID-19 prevention plan. This may increase investor trust.
Supportive ifEarly data from the MDX2301 Phase 1 trial shows it is safe for healthy volunteers.
Worry ifTrial data shows safety concerns or low tolerance.
Why it matters: Results may confirm OPKO's method for treating B-cell lymphoma. This could affect future partnerships.
Supportive ifEarly positive results from the MDX2003 trial show it is safe and fights tumors.
Worry ifResults indicate lack of efficacy or safety issues in the MDX2003 trial.
Why it matters: Changes to revenue guidance may show OPKO's ability to reach growth goals. This can affect investor feelings.
Watch forManagement increases revenue guidance for Q3 2026 to more than $142 million.
Also watch forManagement cuts revenue guidance for Q3 2026 to less than $131 million.